ClinicalTrials.govpublic full text
CD19 & CD20 Bispecific CAR T Cells for Relapsed / Refractory B Cell Hematological Tumors
b-cell lymphoblastic leukemia/lymphoma, car-t, dual-target, relapsed / refractory b cell hematological tumors, interventional, phase1, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 1044888
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.